These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26220184)

  • 1. Interaction of Formulation and Device Factors Determine the In Vitro Performance of Salbutamol Sulphate Dry Powders for Inhalation.
    Muddle J; Murnane D; Parisini I; Brown M; Page C; Forbes B
    J Pharm Sci; 2015 Nov; 104(11):3861-3869. PubMed ID: 26220184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Granulated Lactose as a Carrier for Dry Powder Inhaler Formulations 2: Effect of Drugs and Drug Loading.
    Du P; Du J; Smyth HDC
    J Pharm Sci; 2017 Jan; 106(1):366-376. PubMed ID: 27939234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterisation and deposition studies of recrystallised lactose from binary mixtures of ethanol/butanol for improved drug delivery from dry powder inhalers.
    Kaialy W; Martin GP; Ticehurst MD; Royall P; Mohammad MA; Murphy J; Nokhodchi A
    AAPS J; 2011 Mar; 13(1):30-43. PubMed ID: 21057906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
    Kaialy W; Ticehurst M; Nokhodchi A
    Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
    Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B
    Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation.
    Zeng XM; Martin GP; Tee SK; Ghoush AA; Marriott C
    Int J Pharm; 1999 May; 182(2):133-44. PubMed ID: 10341303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW; Schneider M; Morrical BD; Imanidis G
    J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of carrier morphology on drug delivery by dry powder inhalers.
    Zeng XM; Martin GP; Marriott C; Pritchard J
    Int J Pharm; 2000 Apr; 200(1):93-106. PubMed ID: 10845690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
    Kim KS; Kim JH; Jin SG; Kim DW; Kim JO; Yong CS; Youn YS; Oh KT; Woo JS; Choi HG
    Pharm Dev Technol; 2018 Feb; 23(2):158-166. PubMed ID: 28612675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate.
    Tee SK; Marriott C; Zeng XM; Martin GP
    Int J Pharm; 2000 Nov; 208(1-2):111-23. PubMed ID: 11064216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of peak inspiratory flow rates and pressure drops on inhalation performance of dry powder inhalers.
    Hira D; Okuda T; Ichihashi M; Mizutani A; Ishizeki K; Okada T; Okamoto H
    Chem Pharm Bull (Tokyo); 2012; 60(3):341-7. PubMed ID: 22382414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dry powder formulations for inhalation of fluticasone propionate and salmeterol xinafoate microcrystals.
    Murnane D; Martin GP; Marriott C
    J Pharm Sci; 2009 Feb; 98(2):503-15. PubMed ID: 18506819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
    Kaialy W; Martin GP; Larhrib H; Ticehurst MD; Kolosionek E; Nokhodchi A
    Colloids Surf B Biointerfaces; 2012 Jan; 89():29-39. PubMed ID: 21962946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro.
    Srichana T; Martin GP; Marriott C
    Eur J Pharm Sci; 1998 Dec; 7(1):73-80. PubMed ID: 9845780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate.
    Larhrib H; Zeng XM; Martin GP; Marriott C; Pritchard J
    Int J Pharm; 1999 Nov; 191(1):1-14. PubMed ID: 10556735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the cellular uptake of respiratory aerosols delivered from different devices equivalent?
    Ong HX; Traini D; Loo CY; Sarkissian L; Lauretani G; Scalia S; Young PM
    Eur J Pharm Biopharm; 2015 Jun; 93():320-7. PubMed ID: 25930239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the aerosol performance of dry powder inhalation formulations by interparticulate interaction analysis using inverse gas chromatography.
    Tong HH; Shekunov BY; York P; Chow AH
    J Pharm Sci; 2006 Jan; 95(1):228-33. PubMed ID: 16315225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insight into pressure drop dependent efficiencies of dry powder inhalers.
    Behara SR; Larson I; Kippax P; Stewart P; Morton DA
    Eur J Pharm Sci; 2012 Jun; 46(3):142-8. PubMed ID: 22586728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.